TITLE

Dandy-Walker Malformation-Like Condition Revealed by Refractory Schizophrenia: A Case Report and Literature Review

AUTHOR(S)
Tréhout, Maxime; Zhang, Norbert; Blouet, Marie; Borha, Alin; Dollfus, Sonia
PUB. DATE
December 2018
SOURCE
Neuropsychobiology;2018/2019, Vol. 77 Issue 2, p59
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Dandy-Walker malformation is a rare congenital malformation involving cystic dilatation of the fourth ventricle, enlarged posterior fossa, complete or partial agenesis of the cerebellar vermis, elevated tentorium cerebelli, and hydrocephalus. Previous research highlighted a possible role for the cerebellum in schizophrenia as well as the contribution of underlying brain malformations to treatment resistance. Here, we present a case of a Dandy-Walker malformation-like condition revealed by a refractory schizophrenia in a 24-year-old male patient. We also conduct a literature review of all previously published case reports or case series of co-occurring posterior fossa abnormalities and schizophrenia or psychosis using a PubMed search query to better understand the potential link between these two disorders. Case Presentation: A 9-month hospital stay was needed to address the treatment-resistant psychotic symptoms, and the patient continued to experience moderate symptoms despite the prescription of various antipsychotic and antidepressant medications. After an irregular initial medical follow-up, the patient is currently treated with 350 mg daily clozapine and 20 mg daily prazepam and still exhibits moderate anxiety without delirious thoughts, however allowing him to re-enroll at the university. Regarding the literature, 24 cases published between 1996 and 2017 were identified, reviewed and compared to the present case report. Discussion: This case report and literature review further illuminates the pathophysiology of psychotic disorders including the potential role of the cerebellum, reinforces the importance of a multidisciplinary approach for the neurological and psychiatric management of patients with schizophrenia, and highlights optimal pharmacological management strategies for treatment-resistant schizophrenia.
ACCESSION #
135036694

 

Related Articles

  • Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond. Waddington, John L.; Zhen, Xuechu; O'Tuathaigh, Colm M. P. // Frontiers in Pharmacology;1/29/2020, p1 

    Alongside positive and negative symptomatology, deficits in working memory, attention, selective learning processes, and executive function have been widely documented in schizophrenia spectrum psychosis. These cognitive abnormalities are strongly associated with impairment across multiple...

  • Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry. Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X // Neuropsychopharmacology;Sep2014, Vol. 39 Issue 10, p2485 

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with...

  • Mismatch Negativity Indices as a Prognostic Factor for Remission in Schizophrenia. Ji Sun Kim; Young Joon Kwon; Hwa Young Lee; Ho-Sung Lee; Sungkean Kim; Se-hoon Shim // Clinical Psychopharmacology & Neuroscience;Feb2020, Vol. 18 Issue 1, p127 

    Objective: Mismatch negativity (MMN) is known to be associated with neuro-cognition and functional outcomes. Remission and recovery rates are related to the neuro-cognition of patients with schizophrenia. The present study explored the relationship of MMN with remission in patients with...

  • In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia. Kaczor, Agnieszka A.; Kȩdzierska, Ewa; Koszła, Oliwia; Targowska-Duda, Katarzyna M. // Biomolecules (2218-273X);Jan2020, Vol. 10 Issue 1, p1 

    Schizophrenia (SZ) is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms, and is not satisfactorily treated by current antipsychotics. Progress in understanding the basic pathomechanism of the disease has been hampered by the lack of appropriate models. In...

  • Clozapine/risperidone/valproate interaction: Myocarditis: case report.  // Reactions Weekly;2/8/2020, Vol. 1790 Issue 1, p84 

    On admission, he started receiving treatment with clozapine 25 mg/day and the dose was increased to 100 mg/day on day 15. After 18 days of clozapine initiation, an ECG revealed re-polarisation abnormalities in the inferior leads, sinus tachycardia and normal QRS complex duration. Therefore,...

  • Diffusion tensor analysis in chronic schizophrenia A preliminary study on a high–field (3.0T) system. Kitamura, Hideaki; Matsuzawa, Hitoshi; Shioiri, Toshiki; Someya, Toshiyuki; Kwee, Ingrid L.; Nakada, Tsutomu // European Archives of Psychiatry & Clinical Neuroscience;2005, Vol. 255 Issue 5, p313 

    The objective of this study was to delineate further the nature of diffusion anisotropy abnormalities in frontal white matter previously observed in schizophrenic patients using a high–field magnetic resonance imaging (MRI) system. Six schizophrenia patients and six healthy control...

  • Aripiprazole monotherapy in an adolescent worsens psychosis. Panigrahi, Mahima; Padhy, Susanta Kumar; Rathi, Rajesh // Indian Journal of Pharmacology;Mar/Apr2013, Vol. 45 Issue 2, p195 

    Early detection and treatment of early onset schizophrenia (EOS) can lead to better outcome. Aripiprazole, a partial agonist of dopamine and a second generation antipsychotic, has been approved specifically for treatment of children with schizophrenia of aged 13-17 years. Though the use of this...

  • Review of depot aripiprazole for schizophrenia. Bilal Motiwala, Farha; Stasia Siscoe, Kim; El-Mallakh, Rif S. // Patient Preference & Adherence;2013, Vol. 7, p1181 

    Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will...

  • Cerebellar vermis volume in major depressive disorder. Yucel, Kaan; Nazarov, Anthony; Taylor, Valerie; Macdonald, Kathryn; Hall, Geoffrey; MacQueen, Glenda // Brain Structure & Function;Jul2013, Vol. 218 Issue 4, p851 

    The vermis is located in the midline of the cerebellum and is involved in the regulation of affect and cognitive processes. Although changes in vermis size have been reported in several psychiatric disorders such as schizophrenia and bipolar disorder, no volumetric studies have been conducted on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics